Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer

被引：9

作者：

Jacobs N.L. ^{[1
]}

Que F.G. ^{[2
]}

Miller R.C. ^{[3
]}

Vege S.S. ^{[4
]}

Farnell M.B. ^{[2
]}

Jatoi A. ^{[5
]}

机构：

[1] Department of Internal Medicine, Mayo Clinic, Rochester, MN

[2] Department of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN

[3] Department of Radiation Oncology, Mayo Clinic, Rochester, MN

[4] Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN

[5] Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester

来源：

Journal of Gastrointestinal Cancer | 2009年 / 40卷 / 1-2期

关键词：

Morbidity; Mortality; Pancreas cancer; Survivorship;

D O I：

10.1007/s12029-009-9082-y

中图分类号：

学科分类号：

摘要：

Background: Less than 5% of patients diagnosed with exocrine pancreas cancer live to be long-term survivors (5+ years after diagnosis). As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues. Methods: One thousand eight hundred thirty consecutive patients who had exocrine pancreas cancer had been seen at the Mayo Clinic between 1995 and 2001 and who had well-documented evidence of having lived for 5+ years were the focus of this study. Results: Only 85 patients (4.6%) met all the above criteria. These patients had a median age of 65 years with a slight female predominance (53%). Eighty-one (95%) were treated with surgery, 42 (49%) with chemotherapy, and 41 (48%) with radiation. Cumulative morbidity included one or more subsequent surgeries in 17 patients (20%), one or more major infections in 14 (16%), diabetes in 39 (45%), depression in 16 (19%), and a second malignancy in 17 (20%). Twenty-nine patients were deceased at the time of this report; 15 (18%) died from recurrent pancreas cancer more than 5 years after their original diagnosis. Conclusion: Long-term survivors of exocrine pancreas cancer confront notable rates of cumulative morbidity, which include subsequent major surgeries, major infections, diabetes, depression, and second malignancies, as well as late deaths from pancreas cancer itself. © 2009 Humana Press Inc.

引用

页码：46 / 50

页数：4

共 10 条

[1] Tempero M., Brand R., Pancreatic cancer, chap 204, Cecil's Textbook of Medicine, (2007)
[2] Aleman B.M.P., Van Leeuwen F.E., Are we improving the long-term burden of Hodgkin's Lymphoma patients with modern treatment?, Hematology/Oncology Clinics of North America, 21, 5, pp. 961-975, (2007)
[3] Koontz B.F., Kirkpatrick J.P., Clough R.W., Prosnitz R.G., Gockerman J.P., Moore J.O., Prosnitz L.R., Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: Cure balanced against complications, Journal of Clinical Oncology, 24, 4, pp. 605-611, (2006)
[4] Sasieni P.D., Adams J., Cuzick J., Avoidance of premature death: A new definition for the proportion cured, J Cancer Epidemiol Prev, 7, pp. 165-7, (2002)
[5] Strasberg S.M., Drebin J.A., Soper N.J., Evolution and current status of the whipple procedure: An update for gastroenterologists, Gastroenterology, 113, 3, pp. 983-994, (1997)
[6] Burris H.A., Moore M.J., Anderson J., Et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J Clin Oncol, 15, pp. 2403-13, (1997)
[7] Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, New England Journal of Medicine, 350, 12, pp. 1200-1210, (2004)
[8] Wee C.C., Hamel M.B., Huang A., Et al., Obesity and undiagnosed diabetes in the US, Diabetes Care, 31, pp. 1813-5, (2008)
[9] Murphy J.M., Burke J.D., Monson R.R., Et al., Mortality associated with depression: A forty-year prospective from the Stirling County Study, Soc Psychiatry Psychiatr Epidemiol, 43, pp. 594-601, (2008)
[10] Schelldorfer T., Ware A.L., Sarr M.G., Et al., Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible?, Ann Surg, 247, pp. 456-62, (2008)

← 1 →